Papillary thyroid carcinoma: 35-Year outcome and prognostic factors in 1858 patients

Clinical Nuclear Medicine

Volumn 32, Issue 6, 2007, Pages 440-444

  Pelizzo, Maria Rosa ^a   Boschin, Isabella Merante ^a   Toniato, Antonio ^a   Piotto, Andrea ^a   Pagetta, Costantino ^a   Gross, Milton D ^b   Al Nahhas, Adil ^c   Rubello, Domenico ^d  

^a UNIVERSITY OF PADOVA   (Italy)

^b Ann Arbor Health System   (United States)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Disease recurrence; Long term outcome; Papillary thyroid cancer; Prognostic factors; Survival

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; THYROGLOBULIN; THYROXINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ECHOGRAPHY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SCHOOL CHILD; SCORING SYSTEM; SURVIVAL RATE; THORAX RADIOGRAPHY; THYROID PAPILLARY CARCINOMA; THYROID SURGERY; THYROIDECTOMY; UNIVARIATE ANALYSIS; VARIANCE; WHOLE BODY SCINTISCANNING;

ADENOCARCINOMA, PAPILLARY; ADULT; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INTRAOPERATIVE COMPLICATIONS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; THYROID NEOPLASMS; THYROIDECTOMY; THYROXINE;

EID: 34249016629     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31805375ca     Document Type: Article

References (25)

1. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447-1463.
2. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Eng J Med. 1998;338:297-306.
3. Salvesen H, Njolstad PR, Akslen LA, et al. Papillary thyroid carcinoma: a multivariate analysis of prognostic factors including an evaluation of the p-TNM staging system. Eur J Surg. 1992;158:583-589.
4. Hindié E, Melliere D, Lange F, et al. Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? Eur J Nucl Med Mol Imaging. 2003;30:974-981.
5. Casara D, Rubello D, Saladini G, et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med. 1993;34:1626-1631.
6. Roas Pelizzo M, Toniato A, Boschin IM, et al. Locally advanced differentiated thyroid carcinoma: a 35-year mono-institutional experience in 280 patients. Nucl Med Commun. 2005;26:965-968.
7. Kjellman P, Zedenius J, Lundell G, et al. Predictors of outcome in patients with papillary thyroid carcinoma. Eur J Surg Oncol. 2006;32:345-352.
8. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050-1057.
9. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418-428.
10. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid. 1999;9:421-427.
11. Hay ID, Grant CS, Taylor WF, et al. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 1987;102:1088-1095.
12. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947-953.
13. American Joint Committee Thyroid Cancer. AJCC Cancer Staging Handbook. 6th ed, chapter 8. New York, Springer; 2002:89-98.
14. Loh KC, Greenspan FS, Gee L, et al. Pathological tumour-node-metastases (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab. 1997;82:3553-3562.
15. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940 -1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26:879-885.
16. Van Nguyen K, Dilawari RA. Predictive value of AMES scoring system in selection of extent of surgery in well differentiated carcinoma of thyroid. Am Surg. 1995;61:151-155.
17. Pasieka JL, Zedenius J, Auer G, et al. Addition of nuclear DNA content to the AMES risk-group classification for papillary thyroid cancer. Surgery. 1992;112:1154-1159.
18. Dean DS, Hay ID. Prognostic indicators in differentiated thyroid carcinoma. Cancer Control. 2000;7:229-239.
19. Lo CY, Chan WF, Lam KY, et al. Optimizing the treatment of AMES high-risk papillary thyroid carcinoma. World J Surg. 2004;28:1103-1109.
20. Shah JP, Loree TR, Dharker D, et al. Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg. 1992;164:658-661.
21. Shaha AR, Shah JP, Loree TR. Risk group stratification and prognostic factors in papillary carcinoma of thyroid. A. Surg Oncol. 1996;3:534-538.
22. Leboulleux S, Rubino C, Baudin E, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab. 2005;90:5723-5729.
23. Reference deleted in proof.
24. Reference deleted in proof.
25. Byar DP, Green SB, Dor P, et al. A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer. 1979;15:1033-1041.